Recommended Free Tools
Singapore’s Precision Health Research (PRECISE) and technology company Temus announced a five-year Joint Innovation Centre on 2 October 2026. It is an institutional research and engineering collaboration intended to support Phase III of Singapore’s National Precision Medicine programme—not a clinic offering genetic tests or medical advice to the public.
What the PRECISE–Temus centre is intended to do
The parties signed a memorandum of understanding to establish the PRECISE–Temus Joint Innovation Centre (JIC). Its announced remit is to build and maintain capabilities needed to manage genomic data and support research and clinical application. The centre’s specific plans include:
As an Amazon Associate I earn from qualifying purchases.
- Strengthening digital infrastructure, operating models and safeguards for secure, responsible genomic-data management.
- Developing shared platforms for scientists and engineers to process and analyse whole-genome data.
- Assessing emerging methods and technologies, including AI-enabled tools.
- Building specialist delivery capability in computational biology and bioinformatics through talent pathways and live projects.
These are aims for the collaboration, not a list of capabilities the announcement says are already fully in operation. The announcement describes safeguards at a high level; it does not publish a detailed technical security specification. Temus’s 2 October 2026 announcement presents the centre as a way to keep platforms current while supporting research and care without compromising security or scientific quality.
How it fits Singapore’s National Precision Medicine programme
PRECISE coordinates Singapore’s multi-phase National Precision Medicine (NPM) programme. Phase II sequenced 100,000 Singaporeans and conducted clinical implementation studies. Phase III works with the country’s three healthcare clusters to evaluate how genomics can be used in practice and integrated responsibly into clinical care, according to PRECISE’s programme description, last updated 3 July 2026.
#1 Best Overall
The JIC is intended to support that work with data platforms, operating capabilities and specialist expertise. It is not the same thing as the programme’s clinical evaluation: the centre develops and sustains institutional capabilities, while Phase III evaluates genomics’ application in healthcare.
At the Phase III launch on 14 November 2025, Singapore’s Ministry of Health said the plan was to recruit a further 400,000 to 450,000 participants over an expected six years. Those figures describe the plan stated at launch, not a verified current enrolment count. The ministry said the programme would generate population-specific evidence to inform responsible use of genomics in healthcare. The launch speech also framed clinical application as a step-by-step, use-case-driven effort alongside research.
What the reported data figures mean
Temus’s announcement describes earlier PRECISE–Temus work and plans for larger infrastructure. The figures are tied to separate dated accounts and should not be treated as one reconciled measure:
Quick wins for a faster PC:
Repair Windows errors before they cause bigger problemsFix Now →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →| Account | Reported scale or result | Qualification |
|---|---|---|
| Temus announcement, 2 October 2026 | Infrastructure planned to handle about 13.6 petabytes of genomic data and scale beyond 60 petabytes; processing timelines cut from weeks to days; genome-wide association results generated for 100,000 genomes. | Figures and plans reported by Temus in its announcement. The announcement does not establish that the new centre has already delivered the planned scale-up. |
| Temus case study, 9 October 2025 | An earlier pipeline for more than 100,000 genomes, with around 150 TB total data volume and processing time reduced from weeks to days. | A separately scoped earlier-pipeline account; the source does not reconcile its 150 TB figure with the later 13.6-petabyte plan. |
The 2026 announcement also describes the earlier collaboration as generating genome-wide association results for 100,000 genomes. That should not be confused with a claim that the JIC itself has completed a new analysis. Temus’s 2025 case study and its 2026 announcement report different scopes and dates, so their volume figures should remain distinct.
Is the centre a public genetic-testing clinic?
No such service is described in the announcement. The JIC is an institutional infrastructure and capability-building collaboration. The available description does not say that individuals can book testing there, receive personal results or obtain medical advice or treatment from the centre.
Singapore’s Health Minister described genomic information as sensitive and emphasized a measured approach to applying genomics in clinical care. The same ministry speech discussed a separate PRECISE–AWS partnership for secure, scalable, cloud-native genomic infrastructure. That AWS collaboration is distinct from the PRECISE–Temus JIC; they should not be treated as a single partnership. The ministry’s 1 October 2026 speech describes the broader partnership context.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What remains to be established
The announcement sets out goals for shared platforms, data safeguards, technology assessment and specialist talent development. It does not provide a detailed security design, publish comparative clinical outcomes attributable to the JIC, or establish that the planned infrastructure scale has been reached. Those distinctions matter: the centre is being launched to support the programme’s work, not presented as proof that genomic care has already changed for patients.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
